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Sir,
Pemphigus vulgaris (PV) developing in conjunction
with D-penicillamine treatment is a rare disorder; to
date the number of described cases is about 100 (1).
Most reports of D-penicillamine-induced PV are in
patients with rheumatoid arthritis (RA) (2), but there
are no data in the medical literature about this com-
plication in systemic sclerosis-rheumatoid arthritis
SSc-RA overlap syndrome. We here report a case of
D-penicillamine-induced PV in a patient with SSc-RA
overlap syndrome. Discontinuation of the offending
agent and a high dose of methylprednisolone were
required to terminate the disease flare.
CASE REPORT
A 62-year-old white woman had a 10-year history of
symmetrical polyarthritis, with morning stiffness lasting
more than an hour. In November 2000 she was referred to
the dermatology unit with typical diffuse cutaneous sclerosis,
bilateral swollen and tender wrists, metacarpophalangeal,
proximal interphalangeal and ankle joints, eye and oral
dryness, and a sensation of foreign body in her eyes.
Abnormal Schirmer’s (4 mm/5 min), rose Bengal tests and
decreased non-stimulated salivary gland excretion (0.1 ml/
15 min) were found. The laboratory examinations showed
increased ESR (120 mm/1st h), hypergammaglobulinaemia
(20.71 g/l) and raised CRP level (16.5 ml/l). All other
laboratory parameters, including haematology and biochem-
istry, were normal. The immunserology showed granular
ANA positivity in the HEp-2 cell line and rheumatoid factor
positivity, while autoantibody screening was negative for
ENA, Sm/RNP, SSA, SSB and Scl-70 (topoisomerase I). She
underwent extensive examinations, the results of which did
not show any internal organ involvement or erosions in the
small joints. Multiple blood, stool and urine cultures and
serological investigations for known viruses were negative.
The diagnosis of Sjo¨gren syndrome secondary to SSc was
made; saliva and tear supplementation, ACE inhibitor,
colchicine, pentoxiphyllin, vitamin E, NSAID and PUVA
treatment were initiated. The patient showed signs of clinical
improvement, but missed the regular follow-up controls for a
year. In November 2001 she began taking D-penicillamine
300 mg daily, following the advice of a relative without
consulting her physician. In February 2002 she was
hospitalized at the rheumatology department because her
skin symptoms worsened and she had typical RA-like
polyarthritis affecting the wrists, metacarpophalangeal, pro-
ximal interphalangeal joints, right knee and the ankle joints.
Radiological examination showed erosions on bilateral
styloids, and the laboratory examination found anti-ENA,
-SSA and -SSB positivity. SSc-RA overlap syndrome was
diagnosed, and the dose of D-penicillamine was increased up
to 450 mg daily, with physiotherapy and PUVA treatment
being initiated in addition to ongoing medication. Her joint
pain decreased, the skin softened, and her general health
status and movement capabilities improved significantly. Ten
days after the initiation of higher dose D-penicillamine,
erosions and ulcers developed on the inner surface of the lips
(Fig. 1). Mouth balm was applied.
At the end of February she again reported to the
dermatology unit with enlarged and painful lip ulcers and
blisters that appeared throughout the body. Nicolsky’s sign
was positive, the histological examination showed perivascular
lymphocytic infiltration, oedema and incipient acantholysis.
Direct immunofluorescence demonstrated IgG and C3 staining
along the epidermal cell surface membranes. Immunoblot
analysis showed autoantibodies against the 130-kd desmoglein-
3 (Fig. 2). A diagnosis of D-penicillamine-induced pemphigus
vulgaris was made, the penicillamine treatment was stopped,
and methylprednisolone 64 mg daily was started. Seven days
later the skin and mucosal symptoms had disappeared, and
the steroid was tapered and finally discontinued by the end of
May 2002. As a disease-modifying agent methotrexate was
given 7.5 mg weekly. Since then she has not been given steroid
treatment and has been in remission for the past 17 months.
DISCUSSION
The definition of overlap syndromes is somewhat con-
troversial in the medical literature. Most authors use this
term for the coexistence of two distinct clinical entities.
Some of them are relatively common, (RA-SLE, RA-
Sjo¨gren syndrome, RA-polymyositis, SLE-polymyositis),
while others are relatively rare. The overlap between SSc
and RA is less common, and represents a distinct clinical
Fig. 1. Ulcers on the inside of the lip.
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entity with generalized skin sclerosis and severe erosive
polyarthritis (3).
During the past two decades, D-penicillamine has
frequently been prescribed for patients with SSc in spite
of significant adverse effects. Of particular interest is the
association between penicillamine treatment and a wide
variety of autoimmune disorders, including myasthenia,
immune complex nephritis, thyroiditis, polymyositis, lupus
erythematosus, thrombotic thrombocytopenic purpura
and Goodpasture’s syndrome. The cutaneous side effects
of penicillamine are summarized in ref. (4). There is a
growing body of evidence that pemphigus may be
induced or exacerbated by penicillamine; about 100
cases have been described in the literature to date (1).
According to evidence gained from two in vitro
studies, some drugs possess strong acantholytic quali-
ties (5). Based on chemical structure two groups of
drugs are distinguished: 1) thiol drugs like penicillamine
and captopril, and 2) others. The clinical behaviour of
pemphigus allows for division into two main groups;
one comprises pemphigus that continues after stopping
the drug, which is referred to as triggered pemphigus.
In all probability this occurs in patients with a previous
predisposition, with only a 15% spontaneous remission
rate (5), while most patients (85%) have true pemphigus
vulgaris. The other group consists of patients with
lesions that clear soon after withdrawal of the drug,
and is called induced pemphigus, with a spontaneous
recovery rate of about 50%.
The pathogenesis of pemphigus connected with drug
exposure is not entirely clear. The proposed mechanisms
are: (i) drug interference with keratinocyte membrane and
desmosomal surfaces, (ii) direct interference with normal
desmosomal function or alteration of its antigenicity, (iii)
production of immunogenic fragments by the enzymatic
cleavage of desmoglein induced by SH groups or
penicillamine, and (iv) a change in suppressor or helper
T-lymphocyte function or both, allowing the formation of
autoantibodies against the 130-kd desmoglein-3 (1, 5, 6).
Emery et al. (7) proved the pathogenetic role of
autoantibodies against the 80-kd extracellular domain
of desmoglein-1 in pemphigus foliaceus and pemphi-
gus vulgaris. Several studies show that the autoanti-
body response is similar in both spontaneous and
drug-induced disease (6, 8). Predisposing factors are
underlying disease (e.g. RA), prolonged treatment,
and, according to some authors, a genetic predisposi-
tion, i.e. HLA A3, B15 positivity (9).
The discontinuation of the offending drug and the
introduction of oral or intravenous corticosteroid are the
standard approaches. In case of refractory symptoms, or
continuous steroid requirement, steroid-sparing agents
(methotrexate, azathioprine, cyclophosphamide) or even
plasmapheresis may be used. Lastly, promising thera-
peutic attempts with the use of long-term intramuscular
sodium thiomalate were described by Penneys et al. (10).
Most reports of penicillamine-induced pemphigus are
in patients with RA, 10 cases have been reported in
patients with SSc (1) and only one case is described in a
patient with mixed connective tissue disease (11). This is
the first publication regarding a patient with SSc-RA
overlap syndrome.
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Fig. 2. Immunoblot analysis showing autoantibodies against the
130-kd desmoglein-3.
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